β-肾上腺素能受体在肿瘤免疫调节中的研究进展

doi:10.3760/cma.j.issn.1007-1245.2023.19.013

摘要/Abstract

摘要：

免疫治疗是一种新型抗肿瘤治疗方式，但由于免疫抑制的存在，使部分免疫治疗患者出现免疫抵抗，免疫调节剂是克服和延缓免疫耐药重要途径之一。目前，改善免疫治疗的方法主要包括激活免疫共刺激信号、阻断免疫共抑制信号、调节肿瘤微环境和靶向T细胞活化等。β-肾上腺素能信号介导的应激与肿瘤免疫之间存在联系，与免疫相关的免疫细胞表面广泛表达β-肾上腺素能受体，并受其相应神经递质的调节，从而影响肿瘤的免疫反应。抑制β-肾上腺素能受体，特别是β2-肾上腺素能受体，能显著改善肿瘤免疫微环境，增强免疫检查点抑制剂、肿瘤疫苗等免疫治疗的疗效。本文综述β-肾上腺素能受体免疫调节作用的研究进展。

关键词:

肿瘤, β-肾上腺素能受体, 免疫治疗, 肿瘤免疫微环境, 进展

Abstract:

Immunotherapy is a new anti-tumor therapy, but due to the existence of immunosuppression, some immunotherapy patients have immune resistance. Immunomodulators are one of the important ways to overcome and delay the immune resistance. At present, the methods of improving immunotherapy mainly include activating immune costimulatory signals, blocking co-immunosuppressive signals, regulating tumor microenvironment, and targeting T cell activation. More and more clinical studies have showed that there is a relationship between β -adrenergic signal-mediated stress and tumor immunity. β -adrenergic receptors are widely expressed on the surface of immune cells related to immunity, and are regulated by their corresponding neurotransmitters, thus affecting the immune response of tumors. It is found that inhibiting β -adrenergic receptor, especially β2- adrenergic receptor, can significantly improve the tumor immune microenvironment and enhance the efficacy of immunotherapy such as checkpoint inhibitors and tumor vaccines. This paper reviews the research progress of immunoregulation of β -adrenergic receptor.

Key words:

Tumor, β-adrenergic receptor, Immunotherapy, Tumor immune microenvironment, Progress

秦梅袁晓莉米亭同王振波.

β-肾上腺素能受体在肿瘤免疫调节中的研究进展 [J]. 国际医药卫生导报, 2023, 29(19): 2720-2723.

Qin Mei, Yuan Xiaoli, Mi Tingtong, Wang Zhenbo.

Research progress on the role of β -adrenergic receptor in tumor immunomodulation [J]. International Medicine and Health Guidance News, 2023, 29(19): 2720-2723.

参考文献

[1] Qiao G, Chen M, Bucsek MJ, et al. Adrenergic signaling: a targetable checkpoint limiting development of the antitumor immune response[J].Front Immunol,2018,9:164.DOI:10.3389/fimmu.2018.00164.
[2] Van Tits LJ, Michel MC, Grosse-Wilde H, et al. Catecholamines increase lymphocyte beta 2-adrenergic receptors via a beta 2-adrenergic, spleen-dependent process[J].Am J Physiol,1990,258(1 Pt 1):E191-202.DOI:10.1152/ajpendo.1990.258.1.E191.
[3] 李晓燕,李亚星,贾漪涛. β-肾上腺素能受体在肿瘤发生和发展中的研究进展[J]. 肿瘤,2021,41(9):650-656.DOI:10.3781/j.issn.1000-7431.2021.2010-0897.
[4] Fu T, Dai LJ, Wu SY, et al. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response[J].J Hematol Oncol,2021,14(1):98.DOI:10.1186/s13045-021-01103-4.
[5] Lv B, Wang Y, Ma D, et al. Immunotherapy: reshape the tumor immune microenvironment[J].Front Immunol,2022,13:844142.DOI:10.3389/fimmu.2022.844142.
[6] Gandhi S, Pandey MR, Attwood K, et al. Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity[J]. Clin Cancer Res,2021,27(1):87-95.DOI:10.1158/1078-0432.CCR-20-2381.
[7] Kennedy OJ, Kicinski M, Valpione S, et al. Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma[J].Eur J Cancer,2022,165:97-112.DOI:10.1016/j.ejca.2022.01.017.
[8] Kokolus KM, Zhang Y, Sivik JM, et al. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice[J].Oncoimmunology,2017,7(3):e1405205.DOI:10.1080/2162402X.2017.1405205.
[9] Yang C, He Y, Chen F, et al. Leveraging β-adrenergic receptor signaling blockade for improved cancer immunotherapy through biomimetic nanovaccine[J].Small,2023,19(14):e2207029.DOI:10.1002/smll.202207029.
[10] Daher C, Vimeux L, Stoeva R, et al. Blockade of β-adrenergic receptors improves CD8+ T-cell priming and cancer vaccine efficacy[J].Cancer Immunol Res,2019,7(11):1849-1863.DOI:10.1158/2326-6066.CIR-18-0833.
[11] Hinkle L, Liu Y, Meng C, et al. The sympathetic nervous system modulates cancer vaccine activity through monocyte-derived cells[J].J Immunol,2021,207(12):3131-3140.DOI:10.4049/jimmunol.2100719.
[12] Nissen MD, Sloan EK, Mattarollo SR. β-adrenergic signaling impairs antitumor CD8+ T-cell responses to B-cell lymphoma immunotherapy[J].Cancer Immunol Res,2018,6(1):98-109.DOI:10.1158/2326-6066.CIR-17-0401.
[13] De Cicco P, Ercolano G, Ianaro A. The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion[J].Front Immunol,2020,11:1680.DOI:10.3389/fimmu.2020.01680.
[14] Mohammadpour H, MacDonald CR, Qiao G, et al. β2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells[J].J Clin Invest,2019,129(12):5537-5552.DOI:10.1172/JCI129502.
[15] Mohammadpour H, MacDonald CR, McCarthy PL, et al. β2-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME[J].Cell Rep,2021,37(4):109883.DOI:10.1016/j.celrep.2021.109883.
[16] Kokolus KM, Capitano ML, Lee CT, et al. Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature[J].Proc Natl Acad Sci U S A,2013,110(50):20176-20181.DOI:10.1073/pnas.1304291110.
[17] Qiao G, Bucsek MJ, Winder NM, et al. β-Adrenergic signaling blocks murine CD8+ T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress[J].Cancer Immunol Immunother,2019,68(1):11-22.DOI:10.1007/s00262-018-2243-8.
[18] Wang JX, Choi SYC, Niu X, et al. Lactic acid and an acidic tumor microenvironment suppress anticancer immunity[J].Int J Mol Sci,2020,21(21):8363.DOI:10.3390/ijms21218363.
[19] Qiao G, Chen M, Mohammadpour H, et al. Chronic adrenergic stress contributes to metabolic dysfunction and an exhausted phenotype in T cells in the tumor microenvironment[J].Cancer Immunol Res,2021,9(6):651-664.DOI:10.1158/2326-6066.CIR-20-0445.
[20] Zou S, Tong Q, Liu B, et al. Targeting STAT3 in cancer immunotherapy[J].Mol Cancer,2020,19(1):145.DOI:10.1186/s12943-020-01258-7.
[21] Balligand JL. β-adrenergic receptors cooperate with transcription factors: the "STAT" of their union[J].Circulation,2016,133(1):4-7.DOI:10.1161/CIRCULATIONAHA.115.019860.
[22] Rébé C, Ghiringhelli F. STAT3, a master regulator of anti-tumor immune response[J].Cancers (Basel),2019,11(9):1280.DOI:10.3390/cancers11091280.
[23] Najafi M, Hashemi Goradel N, Farhood B, et al. Macrophage polarity in cancer: a review[J].J Cell Biochem,2019,120(3):2756-2765.DOI:10.1002/jcb.27646.
[24] Qin JF, Jin FJ, Li N, et al. Adrenergic receptor β2 activation by stress promotes breast cancer progression through macrophages M2 polarization in tumor microenvironment[J].BMB Rep,2015,48(5):295-300.DOI:10.5483/bmbrep.2015.48.5.008.
[25] Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer[J].Cancer Res,2010,70(18):7042-7052.DOI:10.1158/0008-5472.CAN-10-0522.
[26] Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, et al. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth[J].Oncotarget,2015,6(6):4266-4273.DOI:10.18632/oncotarget.2887.
[27] 胡绍雯,朱惠芳. NK细胞在肿瘤免疫治疗中的研究进展[J].中国免疫学杂志,2023,39(6):1318-1325.DOI:10.3969/j.issn.1000-484X.2023.06.043.
[28] Prager I, Liesche C, van Ooijen H, et al. NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing[J].J Exp Med,2019,216(9):2113-2127.DOI:10.1084/jem.20181454.
[29] Hu D, Shen W, Gong C, et al. Grain-sized moxibustion promotes NK cell antitumour immunity by inhibiting adrenergic signalling in non-small cell lung cancer[J].J Cell Mol Med,2021,25(6):2900-2908.DOI:10.1111/jcmm.16320.
[30] Wieduwild E, Girard-Madoux MJ, Quatrini L, et al. β2-adrenergic signals downregulate the innate immune response and reduce host resistance to viral infection[J].J Exp Med,2020,217(4):e20190554.DOI:10.1084/jem.20190554.
[31] Singh A, Ranjan A. Adrenergic receptor signaling regulates the CD40-receptor mediated anti-tumor immunity[J].Front Immunol,2023,14:1141712.DOI:10.3389/fimmu.2023.1141712.
[32] Huang X, Le W, Chen Q, et al. Suppression of the innate cancer-killing activity in human granulocytes by stress reaction as a possible mechanism for affecting cancer development[J].Stress,2020,23(1):87-96.DOI:10.1080/10253890.2019.1645112.
[33] Perego M, Tyurin VA, Tyurina YY, et al. Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils[J].Sci Transl Med,2020,12(572):eabb5817.DOI:10.1126/scitranslmed.abb5817.